All In Biotech

Drug Trial Radar · NCT04321070

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

550

Actual

Start

Sep 9, 2019

Primary completion

Dec 14, 2019

Study completion Mar 6, 2020

Sponsor

Sponsor type
Industry
First posted
Mar 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Conditions

  • Acne Vulgaris

Interventions

  • Clindamycin PhosphateDrug

    A thin film of investigation product will be applied to the affected areas of the face once daily

  • Clindamycin Phosphate RLDDrug

    A thin film of investigation product will be applied to the affected areas of the face once daily

  • PlacebosDrug

    A thin film of investigation product will be applied to the affected areas of the face once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstration of BioequivalenceTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Catawba Research LLC

    Charlotte, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.